Fasting: A Complex, Double-Edged Blade in the Battle Against Doxorubicin-Induced Cardiotoxicity
Cardiovascular Toxicology · 2024
DOI: 10.1007/s12012-024-09925-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cardiovascular Toxicology, 2024. Verfasst von Yiming Meng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Central Laboratory, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, No. 44, Xiaoheyan Road, D…. Hauptthemen laut MEDLINE: Antibiotics, Antineoplastic, Doxorubicin, Fasting, Heart Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 127 Literaturangaben. Gefördert von: Natural Science Foundation of Liaoning Province.
Abstract (Originalsprache)
In recent years, there has been a surge in the popularity of fasting as a method to enhance one's health and overall well-being. Fasting is a customary practice characterized by voluntary refraining from consuming food and beverages for a specified duration, ranging from a few hours to several days. The potential advantages of fasting, including enhanced insulin sensitivity, decreased inflammation, and better cellular repair mechanisms, have been well documented. However, the effects of fasting on cancer therapy have been the focus of recent scholarly investigations. Doxorubicin (Dox) is one of the most widely used chemotherapy medications for cancer treatment. Unfortunately, cardiotoxicity, which may lead to heart failure and other cardiovascular issues, has been linked to Dox usage. This study aims to comprehensively examine the possible advantages and disadvantages of fasting concerning Dox-induced cardiotoxicity. Researchers have investigated the potential benefits of fasting in lowering the risk of Dox-induced cardiac damage to solve this problem. Nevertheless, new studies indicate that prolonged alternate-day fasting may adversely affect the heart's capacity to manage the cardiotoxic properties of Dox. Though fasting may benefit overall health, it is essential to proceed cautiously and consider the potential risks in certain circumstances.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Central Laboratory, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, No. 44, Xiaoheyan Road, Dadong District, Shenyang, 110042, China. cacamym@163.com.
- Department of Biobank, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, No. 44, Xiaoheyan Road, Dadong District, Shenyang, 110042, China.
- Department of Central Laboratory, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, No. 44, Xiaoheyan Road, Dadong District, Shenyang, 110042, China.
- Department of Surgery, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, No. 44, Xiaoheyan Road, Dadong District, Shenyang, 110042, China. taoyulnszlyy@sina.com.
- Department of Medical Imaging, Cancer Hospital of Dalian University of Technology, Liaoning Province Cancer Hospital, No. 44, Xiaoheyan Road, Dadong District, Shenyang, 110042, China. taoyulnszlyy@sina.com.
- Department of Central Laboratory, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, No. 44, Xiaoheyan Road, Dadong District, Shenyang, 110042, China. haozhepiaolnzlyy@sina.com.
Förderung
- Natural Science Foundation of Liaoning Province
Zitieren
APA
Meng, Y., Sun, J., Zhang, G., Yu, T., & Piao, H. (2024). Fasting: A Complex, Double-Edged Blade in the Battle Against Doxorubicin-Induced Cardiotoxicity. Cardiovascular Toxicology. https://doi.org/10.1007/s12012-024-09925-7
Vancouver
Meng Y, Sun J, Zhang G, Yu T, Piao H. Fasting: A Complex, Double-Edged Blade in the Battle Against Doxorubicin-Induced Cardiotoxicity. Cardiovascular Toxicology. 2024. doi:10.1007/s12012-024-09925-7
BibTeX
@article{Meng2024,
author = {Meng, Yiming and Sun, Jing and Zhang, Guirong and Yu, Tao and Piao, Haozhe},
title = {Fasting: A Complex, Double-Edged Blade in the Battle Against Doxorubicin-Induced Cardiotoxicity},
journal = {Cardiovascular Toxicology},
year = {2024},
doi = {10.1007/s12012-024-09925-7}
}
EUVIMED